SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001683168-24-003175
Filing Date
2024-05-09
Accepted
2024-05-09 17:20:56
Documents
48
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR 3/31/24 phio_i10q-033124.htm   iXBRL 10-Q 419743
2 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER phio_ex3101.htm EX-31.1 10324
3 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER phio_ex3201.htm EX-32.1 4119
  Complete submission text file 0001683168-24-003175.txt   2772052

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE phio-20240331.xsd EX-101.SCH 22851
5 XBRL CALCULATION FILE phio-20240331_cal.xml EX-101.CAL 30420
6 XBRL DEFINITION FILE phio-20240331_def.xml EX-101.DEF 93679
7 XBRL LABEL FILE phio-20240331_lab.xml EX-101.LAB 246551
8 XBRL PRESENTATION FILE phio-20240331_pre.xml EX-101.PRE 200398
51 EXTRACTED XBRL INSTANCE DOCUMENT phio_i10q-033124_htm.xml XML 286604
Mailing Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752
Business Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36304 | Film No.: 24931976
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)